As investigators continue efforts to improve outcomes for patients with low-grade serous ovarian cancer, they are expanding investigations beyond chemotherapy.
Research Efforts Under Evaluation in Low-Grade Serous Ovarian Cancer
Ritu Salani, MD, MBA, discusses pathways implicated in low-grade serous ovarian cancer that may be viable for targeted therapy development.
Dr Brown discusses the rationale for the RAMP-301 trial of avutometinib plus defactinib in low-grade serous ovarian cancer.
Jubilee Brown, MD, highlights the RAS/MAPK pathway in low-grade serous ovarian cancer and research with avutometinib/defactinib that prompted RAMP 301.
Jubilee Brown, MD, discusses ongoing investigations into treatments that target the RAS/MAPK pathway in patients with ovarian cancer.
Premal Thaker, MD, MS, discusses how the RAMP-201 trial paved a way for the RAMP-301 trial of avutometinib/defactinib in low-grade serous ovarian cancer.
Premal Thaker, MD, MS, discusses the phase 3 RAMP-301 trial of avutometinib plus defactinib in recurrent low-grade serous ovarian cancer.
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5